MIM
ADMA icon

MetLife Investment Management’s ADMA Biologics ADMA Stock Holding History

MetLife Investment Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Sell
134,496
-1,603,566
-92% -$14.6M 0.01% 1469
2026
Q1 		$15.7M Buy
1,738,062
+356,474
+26% +$5.63M 0.08% 241
2025
Q4 		$25.2M Buy
1,381,588
+71,554
+5% +$1.21M 0.12% 115
2025
Q3 		$19.2M Buy
+1,310,034
New +$22.5M 0.09% 176
2025
Q2 		– Sell
-1,108,911
Closed -$22M – 2742
2025
Q1 		$22M Buy
1,108,911
+972,699
+714% +$16.8M 0.12% 132
2024
Q4 		$2.34M Buy
136,212
+6,060
+5% +$114K 0.01% 961
2024
Q3 		$2.6M Hold
130,152
– – 0.01% 888
2024
Q2 		$1.46M Buy
130,152
+21,693
+20% +$182K 0.01% 1141
2024
Q1 		$716K Sell
108,459
-2,007
-2% -$11K ﹤0.01% 1487
2023
Q4 		$499K Hold
110,466
– – ﹤0.01% 1683
2023
Q3 		$395K Hold
110,466
– – ﹤0.01% 1775
2023
Q2 		$408K Hold
110,466
– – ﹤0.01% 1840
2023
Q1 		$366K Buy
110,466
+23,110
+26% +$79.9K ﹤0.01% 1847
2022
Q4 		$339K Sell
87,356
-10,902
-11% -$33.6K ﹤0.01% 1886
2022
Q3 		$239K Hold
98,258
– – ﹤0.01% 2168
2022
Q2 		$195K Buy
+98,258
New +$193K ﹤0.01% 2341
2020
Q2 		– Sell
-36,875
Closed -$106K – 2298
2020
Q1 		$106K Buy
+36,875
New +$127K ﹤0.01% 2040
2019
Q4 		– Sell
-26,341
Closed -$117K – 2301
2019
Q3 		$117K Buy
+26,341
New +$110K ﹤0.01% 2244

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

MetLife Investment Management's ADMA Position: Q2 2026 in Review

MetLife Investment Management reduced its ADMA Biologics (ADMA) stake by 92% in Q2 2026, selling an estimated $14.6M and leaving 134,496 shares worth $1.13M. The position accounts for 0.01% of the portfolio, ranked #1469.

MetLife Investment Management first reported a position in ADMA in Q3 2019 and has held it in 18 quarters since. The position peaked at $25.2M in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • MetLife Investment Management held 134,496 shares of ADMA Biologics worth $1.13M as of Q2 2026.
  • MetLife Investment Management sold 1,603,566 ADMA Biologics shares in Q2 2026, an estimated $14.6M.
  • ADMA Biologics made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1469 holding.
  • MetLife Investment Management first reported a position in ADMA Biologics in Q3 2019 and has held it in 18 quarters since.
  • MetLife Investment Management's ADMA Biologics position peaked at $25.2M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.